Glaukos (NYSE:GKOS) Given New $160.00 Price Target at Wells Fargo & Company

Glaukos (NYSE:GKOS) had its price objective raised by Wells Fargo & Company from $153.00 to $160.00 in a research report report published on Friday,Benzinga reports. The brokerage currently has an overweight rating on the medical instruments supplier’s stock.

GKOS has been the subject of a number of other reports. UBS Group initiated coverage on shares of Glaukos in a research note on Friday, December 6th. They issued a “buy” rating and a $182.00 price objective for the company. BTIG Research increased their price objective on shares of Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Mizuho raised shares of Glaukos from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $140.00 to $200.00 in a research note on Wednesday. Piper Sandler reissued an “overweight” rating and issued a $180.00 price objective (up from $140.00) on shares of Glaukos in a research note on Monday, January 27th. Finally, Stephens upgraded shares of Glaukos to a “strong-buy” rating in a research report on Monday, December 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Glaukos has a consensus rating of “Moderate Buy” and a consensus target price of $163.25.

Glaukos Stock Down 19.9 %

Shares of GKOS stock opened at $126.03 on Friday. Glaukos has a 12 month low of $83.90 and a 12 month high of $163.71. The stock has a market cap of $6.95 billion, a P/E ratio of -41.73 and a beta of 1.04. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The company has a 50 day simple moving average of $152.75 and a two-hundred day simple moving average of $139.25.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). The firm had revenue of $105.50 million during the quarter, compared to analysts’ expectations of $100.72 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. On average, research analysts expect that Glaukos will post -1.89 earnings per share for the current year.

Insider Buying and Selling

In other Glaukos news, Director Gilbert H. Kliman sold 2,000 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total transaction of $288,020.00. Following the completion of the transaction, the director now owns 32,336 shares in the company, valued at $4,656,707.36. This trade represents a 5.82 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Tomas Navratil sold 3,416 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the transaction, the insider now owns 72,437 shares of the company’s stock, valued at $10,658,380.18. This trade represents a 4.50 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 18,744 shares of company stock worth $2,792,151. 6.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Glaukos

Institutional investors have recently made changes to their positions in the company. Values First Advisors Inc. bought a new stake in shares of Glaukos in the 3rd quarter worth about $25,000. IFP Advisors Inc bought a new stake in shares of Glaukos in the 4th quarter worth about $43,000. Asset Planning Inc bought a new stake in shares of Glaukos in the 4th quarter worth about $90,000. CoreCap Advisors LLC lifted its holdings in shares of Glaukos by 36.4% in the 4th quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier’s stock worth $112,000 after acquiring an additional 200 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd lifted its holdings in shares of Glaukos by 2,263.2% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after acquiring an additional 860 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.